OCM
INDV icon

Oaktree Capital Management’s Indivior Pharmaceuticals INDV Stock Holding History

Oaktree Capital Management’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$251M Sell
6,127,212
-856,890
-12% -$31.1M 3.49% 7
2026
Q1 		$213M Sell
6,984,102
-124,542
-2% -$4.11M 3.25% 6
2025
Q4 		$255M Sell
7,108,644
-250,676,754
-97% -$7.65B 3.63% 7
2025
Q3 		$10.7M Buy
257,785,398
+246,776,273
+2,242% +$5.16B 0.16% 92
2025
Q2 		$162M Hold
11,009,125
– – 2.79% 7
2025
Q1 		$103M Buy
11,009,125
+2,275,577
+26% +$23.9M 2% 9
2024
Q4 		$112M Sell
8,733,548
-788,432
-8% -$8.11M 1.99% 11
2024
Q3 		$94.1M Buy
9,521,980
+5,028,807
+112% +$58.9M 1.51% 18
2024
Q2 		$70.4M Buy
4,493,173
+1,141,937
+34% +$20.6M 1.12% 18
2024
Q1 		$71.7M Buy
+3,351,236
New +$63M 1.13% 19

Other funds holding INDV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return

Oaktree Capital Management's INDV Position: Q2 2026 in Review

Oaktree Capital Management reduced its Indivior Pharmaceuticals (INDV) stake by 12% in Q2 2026, selling an estimated $31.1M and leaving 6,127,212 shares worth $251M. The position accounts for 3.49% of the portfolio, ranked #7.

Oaktree Capital Management first reported a position in INDV in Q1 2024 and has held it in 10 quarters since. The position peaked at $255M in Q4 2025. 338 funds tracked by Wall St. Rank hold INDV as of Q2 2026.

  • Oaktree Capital Management held 6,127,212 shares of Indivior Pharmaceuticals worth $251M as of Q2 2026.
  • Oaktree Capital Management sold 856,890 Indivior Pharmaceuticals shares in Q2 2026, an estimated $31.1M.
  • Indivior Pharmaceuticals made up 3.49% of Oaktree Capital Management's portfolio in Q2 2026, its #7 holding.
  • Oaktree Capital Management first reported a position in Indivior Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
  • Oaktree Capital Management's Indivior Pharmaceuticals position peaked at $255M in Q4 2025.
  • 338 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q2 2026.

Based on Oaktree Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.